English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish
Key Metrics
Welcome!
Support the Social Media Campaign
Strengthening Healthcare
The Value of Biosimilar Medicines
The campaign theme this year is the Value of Biosimilar medicines. Each day of the week we encourage supporters to share different aspects of biosimilar’s value in social media. Click the arrows below for more details and see sample messages in the social toolkit.
Biosimilars: Value for patients
| |
Biosimilars: Value for healthcare professionals, providers and clinical practice
| |
Biosimilars: Value for governments and healthcare systems
| |
Biosimilars: Value for regulators
| |
Join the Biosimilars Movement! |
Interviews
Our last interview during our third Global Biosimilars Week features Dr Cary Adams, CEO of the Union for International Cancer Control (UICC) and Suzette Kox, IGBA Secretary General. It covers the relatively new UICC initiative, namely a different approach to access by the Access to Oncology Medicines (ATOM) Coalition and how biosimilar medicines companies can play a role in the Coalition’s ambition of improving access to essential cancer medicines.
An IGBA Biosimilars Committee White Paper
Embracing Science with Confidence: Adopting the Revised 2022 WHO Biosimilars Guideline
Biosimilar medicines hold the potential to enable equitable access to biologic therapies for patients around the world. The IGBA’s 2021 Biosimilar medicines Access Policy Blueprint identified four key areas where global collaborative action can help achieve the potential for biosimilar medicines.
This paper further elaborates on one of the key areas: Enhancing Regulatory Efficiency for Greater Access.
It discusses how the revised 2022 WHO Biosimilars Guideline (the Guideline) provides a timely opportunity to collectively re-evaluate the way in which regulatory requirements can better advance biosimilar access. The Guideline defines globally acceptable principles for licensing biological products that can be used to harmonize biosimilar medicines regulations around the world. If cohesively adopted by national regulatory authorities, the Guideline can promote more efficient regulatory systems to provide patients with earlier access to safe, effective, high-quality, and lowercost biosimilar medicines.
Biosimilar Resources
View these educational modules to learn how the biosimilar landscape began and how patients and health care systems benefit from biosimilar medicines around the globe.
The era of biological medicines
Since 1980, biological medicines, which are highly complex treatments made by or derived from a biological source, have grown to become an indispensable tool in modern medicine. These safe and effective medicines are targeted to treat many rare and serious diseases and millions of patients have already benefited from these treatments.
Biological medicines – the major social and economic challenges
Health care systems around the globe are under financial stress due to the pandemic, an aging population and rising prevalence of chronic conditions, with pharmaceutical spending expected to reach $1.6 trillion USD globally in the coming years. Biological medicines, while an important tool in treating certain conditions, come at a very high cost and hence are inaccessible for many patients.
Biosimilar medicines – rising to the cost challenge
Biosimilar medicines are biological medicines that are developed to be highly similar to an existing biological medicine, but are more cost-effective. Today, hundreds of biosimilar medicines have been approved around the globe, which brought competition to the marketplace after patent expiry of the original biological. This has produced huge savings and eased financial stress on health care systems and substantially increased patients access to biological treatments.
Biosimilar medicines – a commitment to scientific excellence
With biosimilar medicines, patients and healthcare providers benefit from quality-assured and efficacious therapeutic alternatives. Biosimilar medicine development is target-oriented and comparative, requiring significant investment and state-of-the-art technologies. Extensive evidence is required to demonstrate that a biosimilar medicine is as safe and effective as its reference biologic. Additionally, the same high regulatory standards apply as for any other medicine.
The benefits of biosimilar medicines
Greater competition introduced by biosimilar medicines has many benefits for patients, providers, and health care systems around the world. Biosimilar medicines give providers a broader range of treatment options for their patients and give more patients access to biological treatments. Additionally, by representing cost-effective alternatives to reference biologicals, biosimilar medicines offer health care systems huge savings for the same clinical outcome.
Building on the experience and success of biosimilar medicines
Biosimilar medicines have become an integral part of our health care systems. Today, they are internationally recognized for expanding access to life-saving treatments. Building on the experience and the success of biosimilar medicines supports their increased uptake and safeguards the medical supply chain.
#GlobalBiosimilarsWeek Around the Globe
View organizations or activities helping to build a better future with biosimilar medicines.
PARTICIPATING IN GBW 
IGBA MEMBER 
GBW MEDIA PARTNER
Open List of Participating Organizations
Are You Participating in Global Biosimilars Week?
To add a biosimilars related event or link on the global map, submit the form below.
;
Mark your calendars! The 4th IGBA Global Biosimilars Week will be held November 13-17.
All week, advocates from around the world will raise awareness of #biosimilars using the hashtag #GlobalBiosimilarsWeek.
Check out the announcement video below.
https://bit.ly/41FtwiD
Biosimilars Council #2022top10:
We are proud to have celebrated #GlobalBiosimilarsWeek and raise awareness for the many ways that #biosimilars are benefitting our health care system, including our providers.
Check out our blog: https://bit.ly/3FLdyZZ
Biogen's Ian Henshaw: Why #GlobalBiosimilarsWeek Is Important for Improving Adoption
http://ow.ly/Wclr50MbQAG
It’s #GlobalBiosimilarsWeek and our colleagues shared their thought on what value they believe #Biosimilars bring to the world.
As a leading global biopharmaceutical company, #CelltrionHealthcare remain committed to making a positive contribution to driving the industry forward.
#GlobalBiosimilarsWeek may be over, but the #biosimilars movement is just beginning! Thank you to everyone who participated — we’ll see you next year!
http://ow.ly/BURE50LJAoy
Thank you to IGBA for organizing #GlobalBiosimilarsWeek and to everyone who participated! Education is a key step in understanding the importance of #biosimilar adoption. Please visit http://biosimilarsforum.org to learn more.
Thank you for engaging in the conversation about #biosimilar medicines during #GlobalBiosimilarsWeek! Learn more at http://biosimilarscanada.ca and https://bit.ly/GlobalBiosimilarsWeek.
#GBW22 #biosimilars #biologics #medicines #MakeTheSwitch
Merci d’avoir participé à la conversation sur les médicaments #biosimilaires pendant la #SemaineMondialeDesBiosimilaires ! Apprenez-en davantage au http://biosimilairescanada.ca et https://bit.ly/GlobalBiosimilarsWeek.
#GlobalBiosimilarsWeek #GBW22 #biosimilaire #biologique
#Biosimilars are increasing access to life-changing medicines to patients at more affordable prices.
See here how Teva is working to unlock new possibilities. https://teva.dsmn8.com/f1gMYu2qJf
#GlobalBiosimilarsWeek
#accesstomedicines #Tevapharm
As experts in creating value through our history in generics, we are now building the future in #biosimilars with next-generation biotechnology and our knowledge of complex molecules.
#GlobalBiosimilarsWeek
https://teva.dsmn8.com/exY786HFHf
Join the IGBA GBW LinkedIn event and connect with others: https://lnkd.in/ef6yXKR3
Have a look at the 2022 theme in the video below and join the movement!
Share this video
Media Partners
